It is believed that this process involves the downregulation of L-type voltage-gated calcium channels61 and upregulation of calcium-activated potassium channels.62 The immediacy of the vasodilation has raised questions as to whether the underlying mechanism involves non-genomic actions of testosterone. BMI, body mass index; Ca, calcium; H, hydrogen; HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; K, potassium; O, oxygen; OH, hydroxide; QTc interval, heart-rate–corrected QT interval. Meta-analyses on the topic have also been mixed, with significant differences between the findings of RCTs and observational studies. Since then, the introduction of chemical castration and hormonal therapy has resulted in a decline in use of physical castration. Questions also have been raised regarding the methodological validity and statistical analysis techniques in the study by Vigen et al.27
The authors reported that 23 patients taking testosterone had cardiovascular complications compared with five in the placebo group and on this basis stopped the trial. However, the effect of testosterone replacement therapy on mortality and patient outcome will need to be subject to large, prospective and randomized controlled trials. Coronary heart disease is the biggest underlying cause of heart failure in the Western world.
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. In light of the current evidence, TTh should be considered a viable and beneficial treatment option for men with hypogonadism, provided that these precautions are followed. The expert panel concludes that TTh is safe from a CV standpoint when prescribed to men with clinically confirmed hypogonadism and managed appropriately. This landmark study and others like it have contributed to a better understanding of the conditions under which TTh can be safely administered. The PaTeR panel's document is more of a clinical roadmap, embedding the TRAVERSE results within a broader, ongoing conversation about the nuanced and individualized use of testosterone in practice. They also address concerns about AF and thromboembolic events during TTh, though PaTeR explores these in more detail with a more cautious stance, also regarding the impact of COVID‐19 on TRAVERSE results.
Similar to the previous reports, TRT resulted in a significant increase in hemoglobin levels.36 However, none of the individual prostate-related adverse events significantly differed between groups, including incident prostate cancer, which showed no difference between the TRT group and placebo.34 In 2016, Boyle et al. reported results of a meta-analysis on prostate cancer in TRT trials. The TRT group had a significantly greater incidence of all prostate-related adverse events, with a pooled odds ratio of 1.78 (95% CI, 1.07–2.95). All four studies included in this meta-analysis evaluated the effects of TRT on LVEF as well. The authors also verified that the odds ratio for having hypogonadism was significantly higher in obese men, and there was a statistically significant negative correlation between total T level and BMI.15 Testosterone replacement therapy (TRT) has been shown to decrease fat mass. Whether low T and increased mortality are simply covariates or a causal relationship remains to be proven.
It calls for further research, particularly on long‐term outcomes, genetic polymorphisms influencing androgen sensitivity, and formulation‐specific safety profiles. It critiques earlier studies that suggested harm and calls for regulatory reversal of US FDA warnings. By focusing on these research areas, the TTh evidence base can be enhanced, leading to safer, more effective treatment approaches for men with hypogonadism. However, careful prescribing and monitoring remain essential to balance benefits and risks effectively. With evidence supporting the CV safety of TTh, notably from the TRAVERSE trial, clinicians can manage hypogonadism with greater confidence.
More research is needed to find out why testosterone levels have declined. Researchers measured testosterone levels in 1,532 randomly selected men during three time periods, 1987–89, 1995–97, and 2002–04. But a 2007 study suggests that since 1987, the hormone's levels have fallen in American men independent of age. The most important cardiovascular event is death from heart disease.
Most physiological effects of testosterone are mediated through its interaction with the AR, a ligand-dependent nuclear receptor. Sex hormone–binding globulin (SHBG) is the major carrier protein of testosterone,6 with approximately 60% of testosterone bound to SHBG, and an additional 40% bound to albumin.6 Only 1%-2% of testosterone is unbound or free.7 Although only free testosterone was historically considered to be biologically available, albumin-bound testosterone is now also accepted as being bioavailable, due to its lower binding affinity.7 Some large observational and randomized studies have supported this conclusion, whereas others have suggested a cardioprotective role for testosterone. Atlhough the protective effect of estrogen on cardiovascular health is well-established,3 the effect of testosterone is less clear. Similar advisories have been mandated for certain types of androgen deprivation therapy. Are we failing to treat a large population of men who would benefit from hormone replacement therapy? The literature showed that testosterone replacement should be managed in the same way as thyroid hormone replacement. have been undertaken on the relationship between more general aggressive behavior, and feelings, and testosterone. This increases the reproductive fitness of the parents because their offspring are more likely to survive and reproduce.|This binding plays an important role in regulating the transport, tissue delivery, bioactivity, and metabolism of testosterone. As a result, testosterone which is not bound to SHBG is called free testosterone. The part of the total hormone concentration that is not bound to its respective specific carrier protein is the free part. This additional information could suggest, contrarily, that testosterone may encourage greed or selfishness. However men with high testosterone were significantly 27% less generous in an ultimatum game. For one study, subjects took part in a behavioral experiment where the distribution of a real amount of money was decided. In humans, testosterone appears more to promote status-seeking and social dominance than simply increasing physical aggression.}
RCTs of TTh in men with chronic heart failure of between 1 and 12 months duration with have not reported any safety concerns.25, 32, 33, 34, 35, 36 The study numbers have been relatively small between 20 and 76 with the longest 12 month trial having the largest study number of 76. In these studies there was no of any CV safety concerns with the few reported events between treatment and placebo groups having no significant differences. This evidence supports prescribing TTh with increased confidence in CV safety, provided patients are carefully selected and monitored. Other secondary outcomes included the risk related to myocardial infarction, stroke, CV death, heart failure, and non‐fatal arrhythmias. Results showed no statistically significant increase in CV risk in the TTh group compared with placebo when either primary or secondary end points were considered.7 Unlike prior studies, where CV safety was always a secondary outcome, the TRAVERSE trial's long‐term design enabled a robust assessment of TTh's CV effects. The HEAT (HEmatopoietic Affection by Testosterone) Registry19 also examined TTh's effects, finding both transdermal and intramuscular formulations raised Hct, though thromboembolic events remained low with appropriate monitoring.

Gender: Female

Social links